To include your compound in the COVID-19 Resource Center, submit it here.

Lu AA21004: Phase III data

A double-blind, North American Phase III trial in 600 adult MDD patients showed that once-daily 5 mg Lu AA21004 missed

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE